Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study
ConditionAntiphospholipid Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNew Valley University
About this trial
Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.
Eligibility criteria
Qualifiers
Age ≥18 years.
Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity.
≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)
Disqualifiers
Thrombocytopenia clearly attributable to non APS causes (e.g., chemotherapy, myelodysplastic syndromes, cirrhosis, HIV).
Concomitant conditions strongly affecting survival independent of APS (e.g., metastatic cancer), at investigator discretion
Trial design
Treatments tested in this trial
- Platelet count
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov